A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Clinical trial NCT05673785 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05673785
- Sponsor
- Takeda
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-10
- Primary completion
- 2025-04-27
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.